Mixed connective tissue disease diagnostic study of choice: Difference between revisions
| Line 4: | Line 4: | ||
{{CMG}}; {{AE}} {{SHH}} | {{CMG}}; {{AE}} {{SHH}} | ||
==Overview== | ==Overview== | ||
The diagnostic criteria of Kasukawa include [[Symptom|symptoms]] common to all the diseases involved, presence of [[antibodies]] against the U1snRNP, and selected [[Symptom|symptoms]] typical of each of the particular component diseases separately ([[systemic lupus erythematosus]], [[systemic sclerosis]], [[polymyositis]]). The MCTD can be confirmed when there is at least one common [[symptom]], positive [[antibodies]] reacting with U1RNP, and at least one [[symptom]] from each of the component diseases. | |||
==Diagnostic Criteria== | ==Diagnostic Criteria== | ||
*The diagnostic criteria of Kasukawa are the most widely used criteria, as they are considered to be the most precise which include:<ref name="pmid24461387">{{cite journal |vauthors=Tani C, Carli L, Vagnani S, Talarico R, Baldini C, Mosca M, Bombardieri S |title=The diagnosis and classification of mixed connective tissue disease |journal=J. Autoimmun. |volume=48-49 |issue= |pages=46–9 |date=2014 |pmid=24461387 |doi=10.1016/j.jaut.2014.01.008 |url=}}</ref><ref name="pmid24353496">{{cite journal |vauthors=Latuśkiewicz-Potemska J, Zygmunt A, Biernacka-Zielińska M, Stańczyk J, Smolewska E |title=Mixed connective tissue disease presenting with progressive scleroderma symptoms in a 10-year-old girl |journal=Postepy Dermatol Alergol |volume=30 |issue=5 |pages=329–36 |date=October 2013 |pmid=24353496 |pmc=3858664 |doi=10.5114/pdia.2013.38365 |url=}}</ref> | *The diagnostic criteria of Kasukawa are the most widely used criteria, as they are considered to be the most precise which include:<ref name="pmid24461387">{{cite journal |vauthors=Tani C, Carli L, Vagnani S, Talarico R, Baldini C, Mosca M, Bombardieri S |title=The diagnosis and classification of mixed connective tissue disease |journal=J. Autoimmun. |volume=48-49 |issue= |pages=46–9 |date=2014 |pmid=24461387 |doi=10.1016/j.jaut.2014.01.008 |url=}}</ref><ref name="pmid24353496">{{cite journal |vauthors=Latuśkiewicz-Potemska J, Zygmunt A, Biernacka-Zielińska M, Stańczyk J, Smolewska E |title=Mixed connective tissue disease presenting with progressive scleroderma symptoms in a 10-year-old girl |journal=Postepy Dermatol Alergol |volume=30 |issue=5 |pages=329–36 |date=October 2013 |pmid=24353496 |pmc=3858664 |doi=10.5114/pdia.2013.38365 |url=}}</ref> | ||
**[[Symptom|Symptoms]] common to all the diseases involved ([[Raynaud's phenomenon|Raynaud’s phenomenon]], swollen fingers) | **[[Symptom|Symptoms]] common to all the diseases involved ([[Raynaud's phenomenon|Raynaud’s phenomenon]], swollen fingers) | ||
** | **Presence of [[antibodies]] against the U1 small nuclear [[ribonucleoprotein]] autoantigen (U1snRNP) | ||
**Selected [[Symptom|symptoms]] typical of each of the particular component diseases separately ([[systemic lupus erythematosus]], [[systemic sclerosis]], [[polymyositis]]). | **Selected [[Symptom|symptoms]] typical of each of the particular component diseases separately ([[systemic lupus erythematosus]], [[systemic sclerosis]], [[polymyositis]]). | ||
*The mixed connective tissue disease can be confirmed when there is at least one common [[symptom]], positive [[antibodies]] reacting with U1RNP, and at least one [[symptom]] from each of the component diseases. | *The mixed connective tissue disease can be confirmed when there is at least one common [[symptom]], positive [[antibodies]] reacting with U1RNP, and at least one [[symptom]] from each of the component diseases. | ||
Revision as of 16:42, 18 April 2018
|
Mixed connective tissue disease Microchapters |
|
Differentiating Mixed connective tissue disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Mixed connective tissue disease diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Mixed connective tissue disease diagnostic study of choice |
|
FDA on Mixed connective tissue disease diagnostic study of choice |
|
on Mixed connective tissue disease diagnostic study of choice |
|
Mixed connective tissue disease diagnostic study of choice in the news |
|
Blogs onMixed connective tissue disease diagnostic study of choice |
|
Directions to Hospitals Treating Mixed connective tissue disease |
|
Risk calculators and risk factors for Mixed connective tissue disease diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
Overview
The diagnostic criteria of Kasukawa include symptoms common to all the diseases involved, presence of antibodies against the U1snRNP, and selected symptoms typical of each of the particular component diseases separately (systemic lupus erythematosus, systemic sclerosis, polymyositis). The MCTD can be confirmed when there is at least one common symptom, positive antibodies reacting with U1RNP, and at least one symptom from each of the component diseases.
Diagnostic Criteria
- The diagnostic criteria of Kasukawa are the most widely used criteria, as they are considered to be the most precise which include:[1][2]
- Symptoms common to all the diseases involved (Raynaud’s phenomenon, swollen fingers)
- Presence of antibodies against the U1 small nuclear ribonucleoprotein autoantigen (U1snRNP)
- Selected symptoms typical of each of the particular component diseases separately (systemic lupus erythematosus, systemic sclerosis, polymyositis).
- The mixed connective tissue disease can be confirmed when there is at least one common symptom, positive antibodies reacting with U1RNP, and at least one symptom from each of the component diseases.
References
- ↑ Tani C, Carli L, Vagnani S, Talarico R, Baldini C, Mosca M, Bombardieri S (2014). "The diagnosis and classification of mixed connective tissue disease". J. Autoimmun. 48-49: 46–9. doi:10.1016/j.jaut.2014.01.008. PMID 24461387.
- ↑ Latuśkiewicz-Potemska J, Zygmunt A, Biernacka-Zielińska M, Stańczyk J, Smolewska E (October 2013). "Mixed connective tissue disease presenting with progressive scleroderma symptoms in a 10-year-old girl". Postepy Dermatol Alergol. 30 (5): 329–36. doi:10.5114/pdia.2013.38365. PMC 3858664. PMID 24353496.